CLINICAL_TRIALS
trial_result
· 2018-10-19
Clinical Trial Update: An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma [Phase 2]
Summary
This open-label Phase 2 trial evaluates acalabrutinib (ACP-196) in patients with mantle cell lymphoma, with results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Acerta Pharma BV | Conditions: Mantle Cell Lymphoma (MCL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2018-10-19